. Ameloblastoma is a benign, intraosseous, progressively growing, epithelial, odontogenic neoplasm. and mutations have been reported in ameloblastoma. In this study, we evaluated V600E and L412F mutations; and assessed the relationship between V600E mutant expression and the clinicopathological features in Japanese patients with ameloblastoma. . We examined 24 formalin-fixed paraffin-embedded samples. All specimens were from patients with mandibular ameloblastoma: 20 were conventional ameloblastoma and 4 were unicystic ameloblastoma. The V600E mutation was assessed by Sanger sequencing and immunohistochemistry, and the L412F mutation was assessed only by Sanger sequencing. . Twenty of the 24 (83%) ameloblastoma samples carried the V600E mutation; 22 of the 24 (92%) samples were immunohistochemically positive for BRAF V600E. However, the L412F mutation was not detected in any of them. The V600E mutation status did not correlate with the clinicopathological features, such as age, sex, location, method, recurrence, and subtype. . BRAF inhibitors could be a potential treatment option for Japanese patients with ameloblastoma, harboring the V600E mutation.

Download full-text PDF

Source
http://dx.doi.org/10.1177/10668969211064203DOI Listing

Publication Analysis

Top Keywords

v600e mutation
16
v600e l412f
12
japanese patients
12
patients ameloblastoma
12
ameloblastoma
9
v600e
8
l412f mutations
8
clinicopathological features
8
mutation assessed
8
assessed sanger
8

Similar Publications

Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which treatment is effective as first-line metastatic therapy. This retrospective, multicenter study included 120 patients diagnosed with stage IIIB-IIID melanoma receiving both adjuvant and first-line metastatic treatment between 2007 and 2023.

View Article and Find Full Text PDF

To investigate the expression pattern of pan-TRK protein in colorectal cancers with NTRK gene fusion and mismatch repair deficient (dMMR) and to analyze its molecular pathological characteristics. A total of 117 dMMR colorectal cancers diagnosed in the Department of Pathology of Henan Provincial People's Hospital, Zhengzhou, China from 2020 to 2023 were collected. Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and DNA/RNA-based next-generation sequencing (NGS) were used to detect pan-TRK protein expression and fusion partner genes in tumors, and to further explore the correlation between pan-TRK staining patterns and partner genes.

View Article and Find Full Text PDF

Ganglioglioma, a glioneuronal neoplasm, typically presents in adolescents' temporal lobes. While pediatric brainstem gangliogliomas (BSGGs) are well documented, adult BSGGs are limited, resulting in a lack of comprehensive understanding of their pathophysiology and prognosis. A 41-year-old woman who presented with dizziness and numbness in her right upper extremity and right face underwent radiological examination.

View Article and Find Full Text PDF

A 21-year-old woman presented with progressive proptosis of the right eye with blurring of vision for the past 6 months. MRI showed an intra-orbital lesion that was T1 isointense, T2 hyperintense, and well enhancing on contrast. The patient underwent right frontal craniotomy, superior orbitotomy, and decompression of the lesion.

View Article and Find Full Text PDF

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center's experience.

Front Oncol

January 2025

Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States.

Background: Pediatric low-grade gliomas (pLGGs) have an overall survival of over 90%; however, patients harboring a BRAF alteration may have worse outcomes, particularly when treated with classic chemotherapy. Combined BRAF/MEK inhibition following incomplete resection demonstrated improved outcome in BRAF altered pLGG compared to combined carboplatin/vincristine chemotherapy and is now considered the standard FDA-approved treatment for this group of tumors. The aim herein was to investigate the efficacy and tolerability of single agent BRAF inhibitor treatment in BRAF altered pLGG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!